Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07643610
NCT07643610RecruitingNot Applicable

BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry

University Hospital, Basel, Switzerland1 site in 1 country8,000 target enrollmentStarted: October 1, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
8,000
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay
  • •Age ≥18 years
  • •Provision of written ICF
  • •Clinical diagnosis of cardiogenic shock.
  • •impaired organ perfusion due to primary cardiac dysfunction,
  • •persistent systolic blood pressure (SBP) <90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and
  • •evidence of systemic hypoperfusion with arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l and ≥1 of the following:
  • •Cold or clammy extremities
  • •Altered mental status
  • •Reduced urine output
  • •Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)
  • •Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l) and cardiac dysfunction are present and alternative causes are excluded

Exclusion Criteria

  • •Age <18 years
  • •Refusal to provide informed consent by the patient or their legally authorized representative

Investigators

Sponsor
University Hospital, Basel, Switzerland
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
此为补注册，需在 www.medresman.org.cn 上建立项目、审核原始数据并公示后才能补注册; 请上传伦理审批文件。 NIRS 对危重症患儿脑功能监测的临床应用研究
ChiCTR2200056458贵州省人民医院儿童重症医学科
Recruiting
Not Applicable
Traumatic Cardiac ArrestTrauma
NCT07490171Methodist Health System100
Recruiting
Not Applicable
BIO|STREAM.CSP StudyHeart Failure
NCT07393009Biotronik SE & Co. KG1,000
Not yet recruiting
Not Applicable
Impact of Implementing a National Classification of Surgical Emergencies on Postoperative Morbidity and Mortality: a Prospective Multicenter Observational Study After Implementation.
NCT07317635Société Française d'Anesthésie et de Réanimation2,500
Unknown
Not Applicable
急性胸痛患者早期危险分层与诊治流程研究
ChiCTR2400088432国家心血管疾病临床医学研究中心